ToxSci Advance Access originally published online on February 16, 2005
Toxicological Sciences 2005 86(1):56-60; doi:10.1093/toxsci/kfi126
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Case Study: Weight of Evidence Evaluation of the Human Health Relevance of Thiamethoxam-Related Mouse Liver Tumors
* Syngenta Crop Protection, Inc., P.O. Box 18300, Greensboro, North Carolina 27455, and Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire, United Kingdom
Received November 7, 2004; accepted January 23, 2005
Thiamethoxam (CGA293343; 3-(2-chloro-thiazol-5-ylmethyl)-5-methyl-[1,3,5]oxadiazinan-4-ylidene-N-nitroamine) was shown to increase the incidence of mouse liver tumors in an 18-month study; however, thiamethoxam was not hepatocarcinogenic in rats. Thiamethoxam is not genotoxic, and, given the late life generation of mouse liver tumors, suggests a time-related progression of key hepatic events that leads to the tumors. These key events were identified in a series of studies of up to 50 weeks that showed the time-dependent evolution of relatively mild liver dysfunction within 10 weeks of dosing, followed by frank signs of hepatotoxicity after 20 weeks, leading to cellular attrition and regenerative hyperplasia. A metabolite, CGA330050, was identified as generating the mild hepatic toxicity, and another metabolite, CGA265307, exacerbated the initial toxicity by inhibiting inducible nitric oxide synthase. This combination of metabolite-generated hepatotoxicity and increase in cell replication rates is postulated as the mode of action for thiamethoxam-related mouse liver tumors. The relevance of these mouse-specific tumors to human health was assessed by using the framework and decision logic developed by ILSI-RSI. The postulated mode of action was tested against the Hill criteria and found to fulfill the comprehensive requirements of strength, consistency, specificity, temporality, dose-response, and the collective criteria of being a plausible mode of action that fits with known and similar modes of action. Whereas the postulated mode of action could theoretically operate in human liver, quantitation of the key metabolites in vivo and in vitro showed that mice, but not rats or humans, generate sufficient amounts of these metabolites to initiate the hepatic toxicity and consequent tumors. Indeed, rats fed 3000 ppm thiamethoxam for a lifetime did not develop hepatotoxicity or tumors. In conclusion, the coherence and extent of the database clearly demonstrates the mode of action for mouse liver tumorigenesis and also allows for the conclusion that thiamethoxam does not pose a carcinogenic risk to humans.
Key Words: thiamethoxam; hepatocarcinogenesis; mode of action.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Green, A. Toghill, R. Lee, F. Waechter, E. Weber, and J. Noakes Thiamethoxam Induced Mouse Liver Tumors and Their Relevance to Humans: Part 1: Mode of Action Studies in the Mouse Toxicol. Sci., July 1, 2005; 86(1): 36 - 47. [Abstract] [Full Text] [PDF]
|
|